Trending Topic

Brain head human mental idea mind 3D illustration background
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Cognitive impairment is the hallmark symptom of Alzheimer’s disease (AD); however, neuropsychiatric symptoms (NPS), including psychosis, agitation and mood disturbances, are common not only in AD but also in Parkinson’s disease, dementia with Lewy bodies, frontotemporal dementia and vascular dementia.1–5 Psychotic symptoms have been reported to be present in 12–74% of patients with AD, with […]

3 mins

Cortical Superficial Siderosis of the Central Nervous System – An Overview

Jacques L De Reuck
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Published Online: May 22nd 2014 European Neurological Review, 2014;9(1):68–70 DOI: http://doi.org/10.17925/ENR.2014.09.01.68
Select a Section…
1

Abstract

Overview

Cortical superficial siderosis (cSS) is observed on gradient echo T2*-weighted magnetic resonance imaging (MRI) as a hypo-intensity
outlining the convexity of the cerebral hemispheres. It is composed of haemosiderin deposits in the subpial space. It was initially thought
to be a rare condition but with 7.0 Tesla (T) MRI it appears to be not uncommon. Its symptomatology depends on the underlying cortical
pathology. Diffuse cSS is mainly related to the sequels of an underlying lobar haematoma, mainly due to cerebral amyloid angiopathy (CAA).
Focal cSS is more due to cortical microinfarcts, that underwent haemorrhagic transformation, rather than due to cortical microbleeds.
cSS is not only found in patients suffering from CAA but also in those suffering from several neurodegenerative dementia syndromes and
after cerebral trauma.

Keywords

Cortical superficial siderosis, T2*-weighted magnetic resonance imaging, cerebral amyloid angiopathy, lobar haematoma, cortical microbleed, cortical microinfarct

2

Article

Cortical superficial siderosis (cSS) of the central nervous system is considered a rare condition, observed on gradient echo T2*- weighted magnetic resonance imaging (MRI) as a typical signal hypointensity outlining the brain surface. It is detected as a characteristic curvilinear pattern preferentially affecting the cerebral convexities.1 It reflects haemosiderin deposition in the subpial space, which cannot be removed from the subarachnoid space by the cerebrospinal fluid circulation. 2 In the population-based Rotterdam Scan Study, using a 1.5-Tesla (T) MRI, the overall incidence of SS was found to be 0.7 %, all of whom had cortical microbleeds in their vicinity. 3 It has to be distinguished from the rare classic neurodegenerative syndrome in which SS mainly affects the brainstem and cerebellum. The age of onset of this syndrome ranges from 14 to 77 years leading to death after 1 to 38 years. It is now accepted that classic SS is the result of chronic subarachnoid haemorrhage due to dural pathology or a cervical root lesion, a vascular tumour or a vascular abnormality. 4 Table 1 summarises the frequency of the most common clinical symptoms in this syndrome.

Aetiological Classification
Many disease entities can give raise to cSS: they can have a traumatic (see Figure 1) or a non-traumatic origin (see Table 1). In cSS, with a predilection for the cerebral convexity, cerebral amyloid angiopathy (CAA) is considered as the most common cause in elderly individuals. 5 cSS is reported in 60.5 % of histologically proven cases of CAA6 and in 40 % of a clinico-radiological correlation study. 7 Some authors have even proposed to include cSS in the Boston diagnostic criteria for CAA; 4,7 however, a definite diagnosis of CAA requires a full postmortem examination.8

In our post-mortem 7.0-T MRI study with neuropathological correlates, 45 (37.5 %) out of a series 120 brains of patients with various neurodegenerative and cerebrovascular diseases were found to have SS. Although CAA was the most common cause (33.3 %) it could also be observed in brains of patients with pure Alzheimer’s disease (AD), frontotemporal lobar degeneration, Lewy body disease, progressive supranuclear palsy, corticobasal degeneration and thrombo-embolic strokes. 9

Pathogenesis
The preferential aetiology is different according to the extension of the cSS. In diffuse cSS, involving more than three gyri sequels of a lobar haematoma, mainly due to CAA, is the underlying cause (see Figure 2). In focal cSS, involving fewer than three gyri cortical infarcts, due to atherosclerosis or CAA are most frequently observed (see Figure 3). They are responsible for 67 % of focal cSS compared with 33 % due to cortical microbleeds. 9 Also, in a recent study, showing that SS is a warning sign for future intracranial haemorrhage, the incidence of the concomitant occurrence of cSS and microbleeds was found to be low. 10 A possible explanation is that microbleeds in CAA brains are mainly located in the deep cortical layers and do not frequently extend up to the cortical surface. 11 On the other hand, cortical microinfarcts more frequently involve the cortical surface9 and leakage of blood develops with time, leading to some degree of haemorrhagic transformation in initially white infarcts. 12

Clinical Presentation
The symptomatology of cSS is determined by the underlying cause and disease. In diffuse cSS the clinical presentation will mainly depend on the size and the location of the underlying lobar haematoma, due to CAA. 7

Focal cSS may present as transient focal neurological episodes such as ‘aura-like’ spreading paraesthesias, visual flickering, limb jerking, limb weakness, dysphasia or vision loss. 13 These attacks are frequently recurrent and stereotyped. 14 Focal seizures and migrainous auras may also be presenting symptoms. 15

Patients with AD associated to cSS performed worse in the minimental state examination than those without cSS. 16 In a memory clinic population the incidence of cSS is higher in patients with AD than in those with mild cognitive impairment and other dementia types. 17 Also the clinical presentation of AD with cSS due to CAA is different with mainly prominent aphasia, greater than impaired episodic memory. 18

Treatment
Lipid-soluble deferiprone has been started in some classic SS trials, 19 but the drug cause significant side effects. 20 However, in cSS it is more important to treat the underlying cause than the residues of the subpial bleed. In cases of diffuse cSS the main cause will be a lobar haematoma and prior antithrombotic or anticoagulant agents should be stopped. On the other hand, one can discuss whether the observation of focal cSS should not be an indication to start with an antithrombotic drug.

Discussion
cSS should not be considered as a separate disease entity but as an epi-phenomenon of an underlying cortical pathology. When observed on MRI it could be considered as an additional argument for the clinical diagnosis of CAA, if associated to posterior microbleeds, lobar haematomas and severe white changes according to the Boston criteria. 8

In focal isolated cSS one should enlarge the possible diagnoses. Although microbleeds can now easily be detected by conventional structural MRI, cortical microinfarct detection requires 7.0-T MRI. 21 As these machines are not routinely available one can only suspect a cortical microinfarct when no microbleed adjacent to the focal cSS is observed.

2

References

  1. Kumar N, Neuroimaging in superficial siderosis an in-depth
    look, AJNR Am J Neuroradiol, 2010;31:5–14.

  2. De Reuck J, Reply to the comments of Andreas Charidimou
    and David J Wering, Cerebrovasc Dis, 2013;36:420.

  3. Vernooij MW, Ikram MA, Hofman A, et al., Superficial siderosis
    in the general population, Neurology, 2009;73:202–5.

  4. Linn J, Herms J, Dichgans M, et al., Subarachnoid
    hemosiderosis and superficial cortical hemosiderosis
    in cerebral amyloid angiopathy, AJNR Am J Neuroradiol,
    2008;29:184–6.

  5. Cuvincuic V, Viguier A, Calviere L, et al., Isolated acute
    nontraumatic cortical subarachnoid hemorrhage, AJNR Am J
    Neuroradiol, 2010;31:1355–62.

  6. Linn J, Halpin A, Demaerel P, et al., Prevalence of superficial
    siderosis in patients with cerebral amyloid angiopathy,
    Neurology, 2010;74:1346–50.

  7. Charidimou A, Jager RH, Fox Z, et al., Prevalence and
    mechanisms of cortical superficial siderosis in cerebral
    amyloid angiopathy, Neurology, 2013;81:626–2.

  8. Knudsen KA, Rosand J, Karluk D, Greenberg SM, Clinical
    diagnosis of cerebral amyloid angiopathy: validation of the
    Boston criteria, Neurology, 2001;56:537–9.

  9. De Reuck J, Deramecourt V, Cordonnier C, et al., Superficial
    siderosis of the central nervous system: A post-mortem
    7.0-Tesle magnetic resonance study with neuropathological
    correlates, Cerebrovasc Dis, 2013;36:412–7.

  10. Linn J, Wollenweber FA, Lummel N, et al., Superficial siderosis
    is a warning sign for future intracranial hemorrhage,
    J Neurol, 2013;260:176–81.

  11. De Reuck J, Deramecourt V, Cordonnier C, et al., The impact
    of cerebral amyloid angiopathy on the occurrence of
    cerebrovascular lesions in demented patients with Alzheimer
    features: a neuropathological study, Eur J Neurol, 2011;18:313–8.

  12. Hebbrecht G, Maenhout W, De Reuck J, Comparison of trace
    element alterations and water content in haemorrhagic
    and nonhaemorrhagic cerebral infarcts, Cerebrovasc Dis,
    1994;4:412–6.

  13. Charidimou A, Peeters A, Fox Z, et al., Spectrum of transient
    focal neurological episodes in cerebral amyloid angiopathy:
    multicentre magnetic resonance imaging cohort study and
    meta-analysis, Stroke, 2012;43:2324–30.

  14. Apoil M, Cogez J, Dubuc L, et al., Focal cortical subarachnoid
    hemorrhage revealed by recurrent paresthesias: a clinicoradiological
    syndrome strongly associated with cerebral
    amyloid angiopathy, Cerebrovasc Dis, 2013;36:139–44.

  15. Sakurai K, Tokumaru AM, Nakatsuka T, et al., Imaging
    spectrum of sporadic cerebral amyloid angiopathy:
    multifacede features of a single pathological condition,
    Insights Imaging, 2014; Epub ahead of print

  16. Wollenweber FA, Buerger K, Mueller C, et al., Prevalence
    of cortical superficial siderosis in patients with cognitive
    impairment, J Neurol, 2014;261:277–82.

  17. Zonneveld HI, Goos JD, Wattjes MP, et al., Prevalence of
    cortical superficial siderosis in a memory clinic population,
    Neurology, 2014;82:698–704.

  18. Feldman HH, Maia LF, Mackenzie IRA, et al., Superficial
    siderosis. A potential diagnostic marker of cerebral amyloid
    angiopathy in Alzheimer disease, Stroke, 2008;39:2894–7.

  19. Levy M, Linas R, Pilot safety trial of deferiprone in 10
    subjects with superficial siderosis, Stroke, 2012;43:120–4.

  20. Huprikar N, Gossweiler M, Callaghan M, Bunge P,
    Agranulocytosis with deferiprone treatment of superficial
    siderosis, BMJ Case Rep, 2013; Aug 7 2013.

  21. Van Veluw SJ, Zwanenburg JJ, Engelen-Lee J, et al., In vivo
    detection of cerebral cortical microinfarcts with highresolution
    7T MRI, J Cereb Blood Flow Metab, 2013;33:322–9.
3

Article Information

Disclosure

The author has no conflicts of interest to declare.

Correspondence

Jacques De Reuck, Leopold II laan 96, 9000 Ghent, Belgium. E: dereuck.j@gmail.com
An erratum to this article can be found below.

Received

2014-04-18T00:00:00

4

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup